Tumor Cell Targeting

Targeting cancer cell–specific alterations

Cancer cells exhibit differences from somatic cells due to alterations that promote growth, proliferation, survival, and metastasis.1 These tumor-specific attributes can be selectively targeted through established modalities, such as antibody‑drug conjugates (ADCs); small molecules, like Janus kinase (JAK) and bone morphogenetic protein receptor kinase activin A receptor, type I (ACVR1) inhibitors; and other biological therapies.1-4 GSK is investigating targeted cell therapies in ongoing clinical studies.5

Belantamab mafodotin
Anti-BCMA antibody‑drug conjugate*
GSK2857914
Unconjugated anti-BCMA antibody
Momelotinib
JAK1/2 and ACVR1 inhibitor

BCMA, B-cell maturation antigen; JAK1/2, Janus kinase 1/2; MOA, mechanism of action; MOD, mechanism of disease.

*In-license or other partnership with third party.

This document contains information for healthcare providers and is intended solely for educational purposes. This display includes ongoing clinical trials for both approved and investigational compounds. Some agents are approved in select indications. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov. All clinical study information updated as of April 10, 2023.

References: 1. Lee YT et al. Eur J Pharmacol. 2018;834:188-196. 2. Hafeez U et al. Molecules. 2020;25(20):4764. doi:10.3390/molecules25204764. 3. Levavi H et al. Clin Adv Hematol Oncol. 2022;20(7):456-467. 4. Asshoff M et al. Blood. 2017;129(13):1823-1830. 5. ClinicalTrials.gov. https://clinicaltrials.gov/. Accessed April 10, 2023.